Doubling Survival in Intermediate-Stage HCC: Y90 vs DEB-TACE (TRACE)
Show notes
This episode breaks down the TRACE phase II randomized trial (Dhondt et al., Radiology 2022) comparing glass yttrium-90 radioembolization with doxorubicin drug-eluting bead chemoembolization (DEB-TACE) for unresectable hepatocellular carcinoma. Following, there is an expert commentary by Dr. Evan Lehrman. .
- The Premise: TACE is the recommended treatment for intermediate-stage (BCLC B) HCC, and uncontrolled studies suggested Y90 radioembolization could be a safe and effective alternative. TRACE put the two head to head.
- The Study: A single-center trial at Ghent University Hospital enrolled patients with intermediate-stage HCC, extended to ECOG performance status 1 and to early-stage HCC not eligible for surgery or thermal ablation. At the interim analysis, 72 patients had been randomized: 38 to glass Y90 and 34 to DEB-TACE.
- Efficacy: Median time to progression was 17.1 vs 9.5 months (HR 0.36), and median overall survival was 30.2 vs 15.6 months (HR 0.48), both favoring Y90. The interim result met the prespecified criteria, and the trial was stopped early for efficacy.
- Safety: Grade 3 or higher serious adverse events were 39% vs 53%, and 30-day mortality was 0% vs 8.3%. Neither difference was statistically significant.
- Caveats: The trial was small, single-center and stopped early, and Y90 dosing used standard package-insert dosimetry rather than today's personalized dosimetry.
- Expert Take: Dr. Lehrman places TRACE alongside LEGACY, RASER and DOSISPHERE as one of the trials reshaping locoregional therapy for HCC. He covers why multifocal BCLC B disease is hard to treat, how staged lobar Y90 was used in more than half of the Y90 arm, why personalized dosimetry might make the results even stronger, and the supporting real-world data from the French PROACTIF registry (989 patients at 34 centers).
Tune in to learn whether Y90 should displace DEB-TACE for intermediate-stage HCC.
This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.
Dhondt E, Lambert B, Hermie L, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699-710. doi:10.1148/radiol.211806